Plain-English translation of NCT05847855 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a new blood test called plasma cfDNA fragmentomics can detect pancreatic neuroendocrine tumors earlier than current methods. The test looks for tiny DNA fragments from tumor cells that float in your bloodstream. Researchers hope this simple blood test could catch these rare tumors at an earlier, more treatable stage.
Pancreatic neuroendocrine tumors are hard to catch early—many patients have cancer that has already spread by the time they are diagnosed. Current imaging tests like CT scans and MRI are expensive, not always accurate, and can expose you to radiation. This study hopes to find a simpler, safer blood test that could find these tumors before they spread.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood drawn once before any surgery. Researchers will analyze your blood sample using the new cfDNA fragmentomics test and compare it with samples from healthy volunteers and patients with other pancreatic conditions. The study is recruiting 1,000 participants total across multiple centers, and the main part of your participation is the single blood draw.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Fudan University
Collaborators
West China Hospital
Enrollment target
~1,000 participants
Started
February 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xianjun Yu, MD, PhD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.